BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23823660)

  • 1. Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies.
    Oyer JA; Huang X; Zheng Y; Shim J; Ezponda T; Carpenter Z; Allegretta M; Okot-Kotber CI; Patel JP; Melnick A; Levine RL; Ferrando A; Mackerell AD; Kelleher NL; Licht JD; Popovic R
    Leukemia; 2014 Jan; 28(1):198-201. PubMed ID: 23823660
    [No Abstract]   [Full Text] [Related]  

  • 2. An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia.
    Swaroop A; Oyer JA; Will CM; Huang X; Yu W; Troche C; Bulic M; Durham BH; Wen QJ; Crispino JD; MacKerell AD; Bennett RL; Kelleher NL; Licht JD
    Oncogene; 2019 Jan; 38(5):671-686. PubMed ID: 30171259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.
    Jaffe JD; Wang Y; Chan HM; Zhang J; Huether R; Kryukov GV; Bhang HE; Taylor JE; Hu M; Englund NP; Yan F; Wang Z; Robert McDonald E; Wei L; Ma J; Easton J; Yu Z; deBeaumount R; Gibaja V; Venkatesan K; Schlegel R; Sellers WR; Keen N; Liu J; Caponigro G; Barretina J; Cooke VG; Mullighan C; Carr SA; Downing JR; Garraway LA; Stegmeier F
    Nat Genet; 2013 Nov; 45(11):1386-91. PubMed ID: 24076604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of the regulation of the normal and oncogenic methylation of nucleosomal histone H3 Lys36 by NSD2.
    Sato K; Kumar A; Hamada K; Okada C; Oguni A; Machiyama A; Sakuraba S; Nishizawa T; Nureki O; Kono H; Ogata K; Sengoku T
    Nat Commun; 2021 Nov; 12(1):6605. PubMed ID: 34782608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The NSD2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic Leukemia.
    Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
    Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
    Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
    Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.
    Kuo AJ; Cheung P; Chen K; Zee BM; Kioi M; Lauring J; Xi Y; Park BH; Shi X; Garcia BA; Li W; Gozani O
    Mol Cell; 2011 Nov; 44(4):609-20. PubMed ID: 22099308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the NSD2 interactome: PARP1 PARylation reduces NSD2 histone methyltransferase activity and impedes chromatin binding.
    Huang X; LeDuc RD; Fornelli L; Schunter AJ; Bennett RL; Kelleher NL; Licht JD
    J Biol Chem; 2019 Aug; 294(33):12459-12471. PubMed ID: 31248990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
    Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
    Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro histone lysine methylation by NSD1, NSD2/MMSET/WHSC1 and NSD3/WHSC1L.
    Morishita M; Mevius D; di Luccio E
    BMC Struct Biol; 2014 Dec; 14():25. PubMed ID: 25494638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.
    Coussens NP; Kales SC; Henderson MJ; Lee OW; Horiuchi KY; Wang Y; Chen Q; Kuznetsova E; Wu J; Chakka S; Cheff DM; Cheng KC; Shinn P; Brimacombe KR; Shen M; Simeonov A; Lal-Nag M; Ma H; Jadhav A; Hall MD
    J Biol Chem; 2018 Aug; 293(35):13750-13765. PubMed ID: 29945974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.
    Marango J; Shimoyama M; Nishio H; Meyer JA; Min DJ; Sirulnik A; Martinez-Martinez Y; Chesi M; Bergsagel PL; Zhou MM; Waxman S; Leibovitch BA; Walsh MJ; Licht JD
    Blood; 2008 Mar; 111(6):3145-54. PubMed ID: 18156491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NSD2 as a Promising Target in Hematological Disorders.
    Azagra A; Cobaleda C
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.
    Yang P; Guo L; Duan ZJ; Tepper CG; Xue L; Chen X; Kung HJ; Gao AC; Zou JX; Chen HW
    Mol Cell Biol; 2012 Aug; 32(15):3121-31. PubMed ID: 22645312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.
    Min DJ; Ezponda T; Kim MK; Will CM; Martinez-Garcia E; Popovic R; Basrur V; Elenitoba-Johnson KS; Licht JD
    Leukemia; 2013 Mar; 27(3):686-94. PubMed ID: 22972034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
    Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
    Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer.
    Ezponda T; Popovic R; Shah MY; Martinez-Garcia E; Zheng Y; Min DJ; Will C; Neri A; Kelleher NL; Yu J; Licht JD
    Oncogene; 2013 Jun; 32(23):2882-90. PubMed ID: 22797064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites.
    Pei H; Zhang L; Luo K; Qin Y; Chesi M; Fei F; Bergsagel PL; Wang L; You Z; Lou Z
    Nature; 2011 Feb; 470(7332):124-8. PubMed ID: 21293379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of LEM-14 inhibitor of the oncoprotein NSD2.
    Shen Y; Morishita M; Lee D; Kim S; Lee T; Mevius DEHF; Roh Y; di Luccio E
    Biochem Biophys Res Commun; 2019 Jan; 508(1):102-108. PubMed ID: 30471851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.